Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30023811 | 1.00 | HSD17B10 (0.51) | HSD17B10POLBMAOAMAOBALDH1A1 | |
| SCHEMBL8670731 | 0.83 | MAOB (0.51) | HSD17B10POLBMAOAMAOBALDH1A1 | |
| SCHEMBL25334408 | 0.80 | HSD17B10 (0.44) | HSD17B10POLBMAOAMAOBALDH1A1 | |
| SCHEMBL7365422 | 0.78 | HPGD (0.40) | HSD17B10POLBALDH1A1CYP2C9MEN1 | |
| SCHEMBL31238875 | 0.76 | MAOB (0.43) | HSD17B10POLBMAOAMAOBALDH1A1 | |
| SCHEMBL26130944 | 0.76 | MAOB (0.43) | HSD17B10POLBMAOAMAOBALDH1A1 | |
| SCHEMBL1828531 | 0.75 | HSD17B10 (0.56) | HSD17B10POLBALDH1A1CYP2C9MEN1 | |
| SCHEMBL15413676 | 0.75 | HSD17B10 (0.56) | HSD17B10POLBALDH1A1CYP2C9MEN1 | |
| SCHEMBL8117734 | 0.75 | CYP11B1 (0.49) | ALDH1A1HTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10636018 | 0.75 | POLB (0.61) | HSD17B10POLBALDH1A1CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192683-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | GUANGZHOU FERMION TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192683-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | GUANGZHOU FERMION TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-115991703-A | Ring-fused compound, preparation method thereof, pharmaceutical composition and application | 广州费米子科技有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-113717167-B | Fused ring compound, preparation method thereof, pharmaceutical composition and application | 广州费米子科技有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-113717167-A | Fused ring compound, preparation method thereof, pharmaceutical composition and application | 广州费米子科技有限责任公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021233427-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | 广州费米子科技有限责任公司 | 2021-11-25 | — | — | WO | disclosed |
| WO-2015123228-A1 | PROCESSES FOR THE SYNTHESIS OF INTERMEDIATES OF THE HERBICIDE FLUCETOSULFURON | FMC CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123228-A1 | PROCESSES FOR THE SYNTHESIS OF INTERMEDIATES OF THE HERBICIDE FLUCETOSULFURON | FMC CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| CN-104829524-A | Synthetic method of intermediate of herbicide flucetosulfuron | FMC CORP | 2015-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192683-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SSTR4, SSTR3, NPY4R | HSD17B10 2036/4885POLB 4704/4885MAOA 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.